Wolfgang G. Philipp-Dormston
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wolfgang G. Philipp-Dormston has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
- Koenraad De Boulle
Aalst Dermatology Clinic, Aalst, Belgium
3 shared publications - Karim Sayed
Nomi Oslo Clinic, Oslo, Norway
2 shared publications Mansi Mukherjee
2 shared publicationsA. Jäger
Biofrontera Bioscience GmbH Leverkusen Germany
1 shared publication- Abdullah M. Aleisa1 shared publication
- Ada Regina Trindade de Almeida
Clinica de Dermatologia Hospital Do Servidor Municipal de São Paulo São Paulo Brazil
1 shared publication
Latest Publications
- 23 April 2026
- Published by Springer Nature in European Journal of Plastic Surgery
- Vol. 49 (1) , 60
Facial contraction patterns and their association with psychological well-being: a cross-sectional study
- 23 April 2026
- Published by Springer Nature in European Journal of Plastic Surgery
- Vol. 49 (1) , 60
Facial contraction patterns and their association with psychological well-being: a cross-sectional study
- Open Access
Clinical Olsen Grading Does Not Reflect Basal Growth in Actinic Keratoses: Two-Center Retrospective Analysis
Background/Objectives: Actinic keratosis (AK) is a precancerous lesion that may progress into cutaneous cancer. However, the progression potential of individual lesions remains unpredictable. The histological basal proliferation pattern of AKs may serve as a risk marker for progression, yet it cannot be assessed clinically. The objective was to evaluate whether Olsen grading (hyperkeratosis of AKs) and pain as clinical markers correlate with the histological basal proliferation (PRO) and different histological aspects. Methods: In this retrospective two-center study, 380 clinically diagnosed AKs were graded according to the clinical Olsen classification (I–III) and assessed for pain upon palpation. Histologically, they were classified based on their basal- (PRO I–III) and upward-directed (AK I–III) growth patterns, and additional histopathological features, such as acantholysis, were documented. Results: Olsen grading showed weak correlation with the PRO classification (Spearman’s rho = 0.136, p = 0.008), with exact agreement of 36.3% (κ = 0.07). Pain was significantly associated with higher PRO grades (p = 0.005) and acantholysis (p = 0.023) but not with Olsen grades or upward-directed growth (AK I–III). Conclusions: Olsen grading does not allow reliable prediction of basal proliferation patterns in AKs. Its use as a clinical severity scale may suggest progression relevance; however, no substantiated association with histological indicators of transformation could be demonstrated in this study. The presence of pain, however, correlated with high PRO grades and the presence of acantholysis.
Open AccessClinical Olsen Grading Does Not Reflect Basal Growth in Actinic Keratoses: Two-Center Retrospective Analysis
Background/Objectives: Actinic keratosis (AK) is a precancerous lesion that may progress into cutaneous cancer. However, the progression potential of individual lesions remains unpredictable. The histological basal proliferation pattern of AKs may serve as a risk marker for progression, yet it cannot be assessed clinically. The objective was to evaluate whether Olsen grading (hyperkeratosis of AKs) and pain as clinical markers correlate with the histological basal proliferation (PRO) and different histological aspects. Methods: In this retrospective two-center study, 380 clinically diagnosed AKs were graded according to the clinical Olsen classification (I–III) and assessed for pain upon palpation. Histologically, they were classified based on their basal- (PRO I–III) and upward-directed (AK I–III) growth patterns, and additional histopathological features, such as acantholysis, were documented. Results: Olsen grading showed weak correlation with the PRO classification (Spearman’s rho = 0.136, p = 0.008), with exact agreement of 36.3% (κ = 0.07). Pain was significantly associated with higher PRO grades (p = 0.005) and acantholysis (p = 0.023) but not with Olsen grades or upward-directed growth (AK I–III). Conclusions: Olsen grading does not allow reliable prediction of basal proliferation patterns in AKs. Its use as a clinical severity scale may suggest progression relevance; however, no substantiated association with histological indicators of transformation could be demonstrated in this study. The presence of pain, however, correlated with high PRO grades and the presence of acantholysis.
- Open Access
- 26 April 2025
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 24 (4) , e70170
Why Dosing Matters: A Closer Look at the Dose–Response Relationship With OnabotulinumtoxinA
Background: OnabotulinumtoxinA is licensed in many countries for simultaneous treatment of three areas of the upper face: glabellar lines, 20 U; lateral canthal lines, 24 U; and forehead lines, 20 U.Aims: To assess the onabotulinumtoxinA dosing science and dose–response relationship in the treatment of upper facial lines (UFL).Methods: Key practical questions are addressed using available data.Results: OnabotulinumtoxinA doses were selected for Phase 3 registrational trials based on rigorous dose‐ranging studies. In clinical practice, it is important to consider the relationship between dose and efficacy outcomes, duration, and safety. Interstudy comparison of duration analyses is complicated by the lack of a single comprehensive definition, but trial data with standard onabotulinumtoxinA dosing in the glabella suggest a median effect duration of ~4 months. Treatment of UFL at below the approved dose is associated with a shorter duration, inferior response rates, and lower patient satisfaction; there is no evidence that underdosing reduces adverse event risk. It may therefore be advisable to avoid going below the licensed dose unless there is a clear clinical rationale. By contrast, there is growing evidence that treatment outcomes can be further improved using doses above those currently licensed, without adversely affecting safety—as demonstrated in the glabella. Further studies are needed to assess this in lateral canthal and forehead lines. Additional work is also required to examine potential ceiling doses and better understand the dose–response relationship in patient subgroups.Conclusions: Appropriate dosing of onabotulinumtoxinA is essential for maximizing benefit and ensuring patient satisfaction.
- 26 April 2025
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 24 (4) , e70170
Open AccessWhy Dosing Matters: A Closer Look at the Dose–Response Relationship With OnabotulinumtoxinA
Background: OnabotulinumtoxinA is licensed in many countries for simultaneous treatment of three areas of the upper face: glabellar lines, 20 U; lateral canthal lines, 24 U; and forehead lines, 20 U.Aims: To assess the onabotulinumtoxinA dosing science and dose–response relationship in the treatment of upper facial lines (UFL).Methods: Key practical questions are addressed using available data.Results: OnabotulinumtoxinA doses were selected for Phase 3 registrational trials based on rigorous dose‐ranging studies. In clinical practice, it is important to consider the relationship between dose and efficacy outcomes, duration, and safety. Interstudy comparison of duration analyses is complicated by the lack of a single comprehensive definition, but trial data with standard onabotulinumtoxinA dosing in the glabella suggest a median effect duration of ~4 months. Treatment of UFL at below the approved dose is associated with a shorter duration, inferior response rates, and lower patient satisfaction; there is no evidence that underdosing reduces adverse event risk. It may therefore be advisable to avoid going below the licensed dose unless there is a clear clinical rationale. By contrast, there is growing evidence that treatment outcomes can be further improved using doses above those currently licensed, without adversely affecting safety—as demonstrated in the glabella. Further studies are needed to assess this in lateral canthal and forehead lines. Additional work is also required to examine potential ceiling doses and better understand the dose–response relationship in patient subgroups.Conclusions: Appropriate dosing of onabotulinumtoxinA is essential for maximizing benefit and ensuring patient satisfaction.
- Open Access
- 22 April 2025
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 105, adv43245
Photoaging and Cosmetic Result with Artificial Daylight Photodynamic Therapy Using Methyl Aminolevulinate
Artificial daylight photodynamic therapy with methyl aminolevulinate is an effective and almost painless treatment approach for actinic keratoses. The objective of the prospective, non-interventional, multicentre study ArtLight (NCT05725213) was to gain comprehensive insights into the cosmetic effect of methyl aminolevulinate-artificial daylight photodynamic therapy in patients with actinic keratoses using different artificial daylight systems under real-world conditions. The study enrolled patients with Olsen grade 1 or 2 actinic keratoses on the face and scalp in Germany. Patients were treated with methyl aminolevulinate-artificial daylight photodynamic therapy. The cosmetic effect was assessed via photodamage parameters (global score for photoaging, mottled pigmentation, tactile roughness, telangiectasias, fine lines). Each photodamage variable was recorded on a 5-point scale (0–4). In total, 224 patients (median age: 75.0 years [range 50–91], 85.3% male, 62.5% Olsen grade 2, 55.4% treatment-naive) were treated with methyl aminolevulinate-artificial daylight photodynamic therapy. At month 3, all 5 parameters of photoaging were significantly reduced from baseline (p < 0.001). The majority of patients (81.3%) and investigators (83.6%) rated the cosmetic result as good or very good. Beyond effective eradication of actinic keratoses, field-directed methyl aminolevulinate-artificial daylight photodynamic therapy can improve photoaging symptoms, including tactile roughness, mottled pigmentation, telangiectasis, and fine lines. Thus methyl aminolevulinate-artificial daylight photodynamic therapy provides additional benefits, particularly for patients concerned with cosmetic outcomes during or after treatment.
- 22 April 2025
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 105, adv43245
Open AccessPhotoaging and Cosmetic Result with Artificial Daylight Photodynamic Therapy Using Methyl Aminolevulinate
Artificial daylight photodynamic therapy with methyl aminolevulinate is an effective and almost painless treatment approach for actinic keratoses. The objective of the prospective, non-interventional, multicentre study ArtLight (NCT05725213) was to gain comprehensive insights into the cosmetic effect of methyl aminolevulinate-artificial daylight photodynamic therapy in patients with actinic keratoses using different artificial daylight systems under real-world conditions. The study enrolled patients with Olsen grade 1 or 2 actinic keratoses on the face and scalp in Germany. Patients were treated with methyl aminolevulinate-artificial daylight photodynamic therapy. The cosmetic effect was assessed via photodamage parameters (global score for photoaging, mottled pigmentation, tactile roughness, telangiectasias, fine lines). Each photodamage variable was recorded on a 5-point scale (0–4). In total, 224 patients (median age: 75.0 years [range 50–91], 85.3% male, 62.5% Olsen grade 2, 55.4% treatment-naive) were treated with methyl aminolevulinate-artificial daylight photodynamic therapy. At month 3, all 5 parameters of photoaging were significantly reduced from baseline (p < 0.001). The majority of patients (81.3%) and investigators (83.6%) rated the cosmetic result as good or very good. Beyond effective eradication of actinic keratoses, field-directed methyl aminolevulinate-artificial daylight photodynamic therapy can improve photoaging symptoms, including tactile roughness, mottled pigmentation, telangiectasis, and fine lines. Thus methyl aminolevulinate-artificial daylight photodynamic therapy provides additional benefits, particularly for patients concerned with cosmetic outcomes during or after treatment.
- Open Access
- 1 February 2025
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 18, 431-441
Prevention and Management of Complications With a Hyaluronic Acid–Calcium Hydroxyapatite Hybrid Injectable
Background: A ready-to-use hyaluronic acid–calcium hydroxyapatite (HA-CaHA) hybrid injectable has a dual mode of action for soft-tissue augmentation. Although previous studies have reported a favorable safety profile for HA-CaHA, there is a need for guidelines and recommendations based on real-world clinical experience for the management of complications associated with HA-CaHA. Purpose: This publication provides guidelines and recommendations for the prevention and management of HA-CaHA–related complications. A case study example, treatment algorithms, and injection techniques are included to illustrate the management of complications. Materials and Methods: On January 25, 2023, 13 European physicians were invited to an advisory board meeting to discuss strategies for optimizing patient care, minimizing adverse events (AEs), and identifying data gaps for the prevention and management of complications with HA-CaHA. Results: The management of a subset of AEs, including skin discoloration and edema, was discussed. Small group workshops also shared management algorithms for late noninflammatory adverse reactions, late inflammatory adverse reactions, localized vascular complications, and retinal vascular complications. Best practices for optimal injection techniques were discussed, and injection-technique protocols were developed for treatment sites. Treatment strategies for HA-CaHA–related complications are considered similar to treatment of those resulting from single-agent fillers, and knowledge of anatomy, aseptic technique, correct injection techniques, and appropriate posttreatment care is emphasized. Conclusion: These recommendations on the management of HA-CaHA–related complications may serve as a reference for the broad range of clinicians using HA-CaHA hybrid injectable for different indications and can help optimize patient outcomes and safety.
- 1 February 2025
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 18, 431-441
Open AccessPrevention and Management of Complications With a Hyaluronic Acid–Calcium Hydroxyapatite Hybrid Injectable
Background: A ready-to-use hyaluronic acid–calcium hydroxyapatite (HA-CaHA) hybrid injectable has a dual mode of action for soft-tissue augmentation. Although previous studies have reported a favorable safety profile for HA-CaHA, there is a need for guidelines and recommendations based on real-world clinical experience for the management of complications associated with HA-CaHA. Purpose: This publication provides guidelines and recommendations for the prevention and management of HA-CaHA–related complications. A case study example, treatment algorithms, and injection techniques are included to illustrate the management of complications. Materials and Methods: On January 25, 2023, 13 European physicians were invited to an advisory board meeting to discuss strategies for optimizing patient care, minimizing adverse events (AEs), and identifying data gaps for the prevention and management of complications with HA-CaHA. Results: The management of a subset of AEs, including skin discoloration and edema, was discussed. Small group workshops also shared management algorithms for late noninflammatory adverse reactions, late inflammatory adverse reactions, localized vascular complications, and retinal vascular complications. Best practices for optimal injection techniques were discussed, and injection-technique protocols were developed for treatment sites. Treatment strategies for HA-CaHA–related complications are considered similar to treatment of those resulting from single-agent fillers, and knowledge of anatomy, aseptic technique, correct injection techniques, and appropriate posttreatment care is emphasized. Conclusion: These recommendations on the management of HA-CaHA–related complications may serve as a reference for the broad range of clinicians using HA-CaHA hybrid injectable for different indications and can help optimize patient outcomes and safety.
- Open Access
- 12 December 2024
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 39 (8) , 1449-1459
Long‐term follow‐up of a randomized, double‐blind, phase III , multi‐centre study to evaluate the safety and efficacy of field‐directed photodynamic therapy ( PDT ) of mild to moderate actinic keratosis using BF ‐200 ALA versus placebo and the BF ‐ RhodoLED ® lamp
Background: In actinic keratosis (AK), field cancerization describes areas of skin where multiple visible AK lesions are surrounded by healthy looking skin containing non‐visible (subclinical) lesions. As all AK lesions have a risk of progression to cutaneous squamous cell carcinoma, experts advise field‐directed treatment. Photodynamic therapy (PDT) is an effective field‐directed treatment option for AK; however, long‐term efficacy data are still scarce. Objectives: This publication presents follow‐up data of a phase III study evaluating the efficacy and safety of field‐directed PDT. Methods: The study was conducted in seven centres in Germany. For PDT, participants with AKs on the face and scalp (treatment area of 20 cm 2 ) had received up to two field‐directed PDTs using BF‐200 ALA or placebo, and illumination with narrow‐spectrum red light. Only participants or lesions with complete response 12 weeks after the last PDT were assessed for recurrences. The treatment area was evaluated 6 and 12 months after the last PDT for recurrence, cosmetic outcome and new lesions. Results: Fifty‐four participants in the BF‐200 ALA and 30 in the placebo group entered the follow‐up. The probability of a participant to be initially completely cleared and to remain cleared for 12 months was 57.4% for BF‐200 ALA versus 20.0% for placebo. The probability of a lesion to be initially cleared and remain cleared for 12 months was 85.4% for BF‐200 ALA versus 31.5% for placebo. 83.3% of participants with cosmetic impairment at baseline rated the cosmetic outcome 12 months after PDT with BF‐200 ALA as very good or good. All parameters of skin quality further improved during follow‐up. Conclusions: We showed that effectiveness of field‐directed PDT with BF‐200 ALA and narrow‐spectrum red light was maintained during follow‐up. Based on our results, field‐directed PDT is a beneficial long‐lasting treatment for AK patients. Clinical Trial Registration Numbers: 2013‐002510‐12 (EudraCT); NCT01966120 ( Clinicaltrials.gov ).
- 12 December 2024
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 39 (8) , 1449-1459
Open AccessLong‐term follow‐up of a randomized, double‐blind, phase III , multi‐centre study to evaluate the safety and efficacy of field‐directed photodynamic therapy ( PDT ) of mild to moderate actinic keratosis using BF ‐200 ALA versus placebo and the BF ‐ RhodoLED ® lamp
Background: In actinic keratosis (AK), field cancerization describes areas of skin where multiple visible AK lesions are surrounded by healthy looking skin containing non‐visible (subclinical) lesions. As all AK lesions have a risk of progression to cutaneous squamous cell carcinoma, experts advise field‐directed treatment. Photodynamic therapy (PDT) is an effective field‐directed treatment option for AK; however, long‐term efficacy data are still scarce. Objectives: This publication presents follow‐up data of a phase III study evaluating the efficacy and safety of field‐directed PDT. Methods: The study was conducted in seven centres in Germany. For PDT, participants with AKs on the face and scalp (treatment area of 20 cm 2 ) had received up to two field‐directed PDTs using BF‐200 ALA or placebo, and illumination with narrow‐spectrum red light. Only participants or lesions with complete response 12 weeks after the last PDT were assessed for recurrences. The treatment area was evaluated 6 and 12 months after the last PDT for recurrence, cosmetic outcome and new lesions. Results: Fifty‐four participants in the BF‐200 ALA and 30 in the placebo group entered the follow‐up. The probability of a participant to be initially completely cleared and to remain cleared for 12 months was 57.4% for BF‐200 ALA versus 20.0% for placebo. The probability of a lesion to be initially cleared and remain cleared for 12 months was 85.4% for BF‐200 ALA versus 31.5% for placebo. 83.3% of participants with cosmetic impairment at baseline rated the cosmetic outcome 12 months after PDT with BF‐200 ALA as very good or good. All parameters of skin quality further improved during follow‐up. Conclusions: We showed that effectiveness of field‐directed PDT with BF‐200 ALA and narrow‐spectrum red light was maintained during follow‐up. Based on our results, field‐directed PDT is a beneficial long‐lasting treatment for AK patients. Clinical Trial Registration Numbers: 2013‐002510‐12 (EudraCT); NCT01966120 ( Clinicaltrials.gov ).
- Open Access
- 5 August 2024
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 104, adv40601
A European Consensus on the Consistent Use of the Term “Keratinocyte Cancer”
Keratinocyte-derived skin cancers comprise basal cell carcinoma, squamous cell carcinoma, its precursor actinic keratosis, and Bowen’s disease. Historically, this group of neoplasms has been subsumed under the term non-melanoma skin cancer. However, the term non-melanoma skin cancer can be misleading and lacks precision. Therefore, more precise and reasonable terminology, valuing the relevance of keratinocyte-derived cancer, appears pertinent to meet its clinical and scientific significance. A group of experienced dermato-oncologists initiated a consensus approach to promote the use of the term “keratinocyte cancer” instead of “non-melanoma skin cancer” when referring to carcinomas and their precursors that are derived from keratinocytes. The vote among members of the consensus group indicated unanimous agreement on the consistent use of the term “keratinocyte cancer” instead of “non-melanoma skin cancer”. International delegates also voted in favour of the revised terminology. The more precise and, by means of etiopathogenesis, correct term “keratinocyte cancer” should be consistently used for malignancies originated from keratinocytes. This is expected to have a positive impact on patient–physician communication and gives better justice to this important group of keratinocyte-derived cancers.
- 5 August 2024
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 104, adv40601
Open AccessA European Consensus on the Consistent Use of the Term “Keratinocyte Cancer”
Keratinocyte-derived skin cancers comprise basal cell carcinoma, squamous cell carcinoma, its precursor actinic keratosis, and Bowen’s disease. Historically, this group of neoplasms has been subsumed under the term non-melanoma skin cancer. However, the term non-melanoma skin cancer can be misleading and lacks precision. Therefore, more precise and reasonable terminology, valuing the relevance of keratinocyte-derived cancer, appears pertinent to meet its clinical and scientific significance. A group of experienced dermato-oncologists initiated a consensus approach to promote the use of the term “keratinocyte cancer” instead of “non-melanoma skin cancer” when referring to carcinomas and their precursors that are derived from keratinocytes. The vote among members of the consensus group indicated unanimous agreement on the consistent use of the term “keratinocyte cancer” instead of “non-melanoma skin cancer”. International delegates also voted in favour of the revised terminology. The more precise and, by means of etiopathogenesis, correct term “keratinocyte cancer” should be consistently used for malignancies originated from keratinocytes. This is expected to have a positive impact on patient–physician communication and gives better justice to this important group of keratinocyte-derived cancers.
- Open Access
- 1 May 2024
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 17, 1203-1216
Melasma: A Step-by-Step Approach Towards a Multimodal Combination Therapy
Melasma is a common challenge in the field of pigmentary skin disorders, exerting a significant emotional and psychosocial burden on patients. The persistent and recurring nature of melasma complicates its management in routine clinical practice. This comprehensive review outlines a stepwise, practical approach encompassing diagnostic, preventive and therapeutic strategies for the management of melasma. A thorough exploration of aggravating and exacerbating factors, including sun exposure, hormonal imbalances, photosensitizing medication and cosmetics, is essential for a holistic assessment of the disease. With an emphasis on consistent and effective photoprotection, initial topical treatment modalities target the melanin production and/or the transfer of melanosomes to keratinocytes. Topical tyrosine inhibitors emerge as the first choice for reducing and preventing hyperpigmentation, with compounds such as thiamidol or tranexamic acid (TXA) being preferred for their safety profile over hydroquinone (HQ), kojic acid and arbutin. Combination with chemical peels can further enhance the therapeutic efficacy, even in cases with resistant melasma. In more severe cases, laser- and light-based interventions may be considered, but with the caveat of the likelihood of recurrence within 3– 6 months. Assisted TXA delivery, via either fractional non-ablative laser or microneedling techniques, can further improve clinical outcomes. In conclusion, an optimal melasma management strategy is a multimodal approach, which includes effective photoprotection and a mix of different topical treatments targeting melanin synthesis, the anti-inflammatory environment, senescence and vascularity. Complementary procedures, such as chemical peels, and laser, light-based or microneedling procedures, with or without TXA, can further expedite melanin clearance in more severely affected instances. Individual discussions with patients regarding treatment expectations, recurrence likelihood and potential side effects are paramount to a comprehensive and successful therapeutic journey.
- 1 May 2024
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 17, 1203-1216
Open AccessMelasma: A Step-by-Step Approach Towards a Multimodal Combination Therapy
Melasma is a common challenge in the field of pigmentary skin disorders, exerting a significant emotional and psychosocial burden on patients. The persistent and recurring nature of melasma complicates its management in routine clinical practice. This comprehensive review outlines a stepwise, practical approach encompassing diagnostic, preventive and therapeutic strategies for the management of melasma. A thorough exploration of aggravating and exacerbating factors, including sun exposure, hormonal imbalances, photosensitizing medication and cosmetics, is essential for a holistic assessment of the disease. With an emphasis on consistent and effective photoprotection, initial topical treatment modalities target the melanin production and/or the transfer of melanosomes to keratinocytes. Topical tyrosine inhibitors emerge as the first choice for reducing and preventing hyperpigmentation, with compounds such as thiamidol or tranexamic acid (TXA) being preferred for their safety profile over hydroquinone (HQ), kojic acid and arbutin. Combination with chemical peels can further enhance the therapeutic efficacy, even in cases with resistant melasma. In more severe cases, laser- and light-based interventions may be considered, but with the caveat of the likelihood of recurrence within 3– 6 months. Assisted TXA delivery, via either fractional non-ablative laser or microneedling techniques, can further improve clinical outcomes. In conclusion, an optimal melasma management strategy is a multimodal approach, which includes effective photoprotection and a mix of different topical treatments targeting melanin synthesis, the anti-inflammatory environment, senescence and vascularity. Complementary procedures, such as chemical peels, and laser, light-based or microneedling procedures, with or without TXA, can further expedite melanin clearance in more severely affected instances. Individual discussions with patients regarding treatment expectations, recurrence likelihood and potential side effects are paramount to a comprehensive and successful therapeutic journey.